Taxorest
Taxorest is a complex peptide bioregulator preparation derived from bronchial mucosal tissue, developed to support respiratory function and bronchial health. Research focuses on its potential for COPD management, bronchial epithelial repair, and age-related respiratory decline through tissue-specific gene regulation.
Taxorest is a complex peptide preparation classified as a cytomedine — a tissue-specific bioregulator developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson's research program.
Overview
Taxorest occupies a specific niche within the Khavinson bioregulatory system as the complex cytomedine counterpart to Bronchogen. While Bronchogen is a defined synthetic tetrapeptide (AEDL) with well-characterized DNA-stabilizing properties (Monaselidze et al., 2011), Taxorest is a tissue-extracted peptide mixture containing a broader spectrum of bioactive sequences. The relationship parallels other cytomedine/synthetic pairs in the Khavinson line — for example, Thymalin (complex thymic extract) and Vilon (synthetic dipeptide).
The respiratory system is particularly susceptible to age-related decline, environmental damage, and chronic inflammatory conditions. Bronchial epithelium undergoes progressive changes with aging, including reduced mucociliary clearance, impaired surfactant production, decreased immune surveillance, and increased susceptibility to infections. Taxorest is designed to address these changes through comprehensive peptide-mediated gene regulation in bronchial tissue.
Mechanism of Action
Taxorest's proposed mechanism builds on the well-studied effects of its synthetic counterpart Bronchogen while encompassing a broader range of biological activities due to its complex peptide composition:
- Bronchial epithelial repair through stimulation of ciliated cell regeneration and goblet cell normalization, restoring the mucociliary clearance apparatus that deteriorates with age and chronic disease
- Anti-inflammatory modulation by reducing pro-inflammatory cytokine expression in bronchial tissue, counteracting the chronic low-grade inflammation that drives COPD progression. Kuzubova et al. (2015) demonstrated that peptide bioregulators targeting bronchial tissue can reduce inflammatory markers and prevent pathological remodeling in COPD models
- Surfactant system support through effects on type II pneumocytes and Clara cells, enhancing the production of surfactant proteins and secretory components essential for pulmonary function
- DNA stabilization consistent with Bronchogen's demonstrated ability to increase DNA melting temperature in lung tissue (Monaselidze et al., 2011), but potentially enhanced by additional peptide sequences in the complex mixture
- Gene expression normalization by interacting with transcription factors including CXCL12 and Hoxa family members, which regulate growth and differentiation in respiratory epithelium (Khavinson et al., 2012)
Research
Respiratory Aging
Age-related changes in the respiratory system include reduced elastic recoil, decreased chest wall compliance, impaired gas exchange, reduced mucociliary clearance, and weakened immune defenses. These changes increase susceptibility to pneumonia, exacerbate existing respiratory conditions, and reduce exercise capacity.
The bioregulatory approach to respiratory aging involves restoring gene expression in bronchial tissue to patterns more characteristic of younger tissue. Khavinson's work on tissue-specific peptide effects during aging (Khavinson et al., 2012) showed that bioregulatory peptides have more pronounced effects on older cells, suggesting that Taxorest may be particularly relevant for age-related respiratory decline.
Bronchial Mucosal Integrity
The bronchial mucosa serves as the first line of defense against inhaled pathogens, particles, and irritants. Its integrity depends on the coordinated function of ciliated cells, goblet cells, basal cells, and the underlying submucosa. Disruption of this barrier — whether through infection, inflammation, or aging — leads to increased susceptibility to respiratory disease.
The peptide regulation framework established by Khavinson et al. (2021) supports the concept that tissue-derived peptide complexes can restore mucosal barrier function through multiple simultaneous gene expression changes, an approach that may be more effective than single-target interventions for complex mucosal tissues.
Chronic Obstructive Pulmonary Disease (COPD)
COPD is characterized by progressive airflow limitation, chronic bronchial inflammation, mucus hypersecretion, and destruction of alveolar structures (emphysema). The disease involves pathological remodeling of the bronchial wall, including epithelial metaplasia, submucosal fibrosis, and smooth muscle hypertrophy.
Research on bronchial-targeted bioregulatory peptides has shown significant effects in COPD models. Kuzubova et al. (2015) demonstrated that peptide therapy could modulate the morphofunctional state of bronchial epithelium in rats with obstructive lung pathology, reducing hyperplasia and dysplasia of the epithelium while restoring ciliated cell populations. These findings are directly relevant to Taxorest, which contains a superset of bioactive peptide sequences targeting the same tissue.
Safety Profile
Taxorest has a safety profile consistent with other cytomedine preparations in the Khavinson series. As a complex of naturally occurring low-molecular-weight peptides derived from bronchial tissue, it is rapidly metabolized through normal proteolytic pathways and is not expected to accumulate. These preparations have been used in Russian clinical practice without reports of significant adverse effects.
Formal toxicology studies and controlled clinical trials published in international peer-reviewed journals remain limited for Taxorest specifically. The safety data for its synthetic counterpart Bronchogen, which has shown no significant adverse effects in preclinical studies, provides some indirect support. Individuals with active pulmonary malignancies should exercise caution, as the effects of respiratory bioregulators on neoplastic bronchial cells have not been fully characterized.
Pharmacokinetic Profile
- Half-life
- Not established
Quick Start
- Route
- Oral
Molecular Structure
- Formula
- Not applicable (polypeptide complex)
- CAS
- Not available
Research Protocols
inhaled Injection
Bronchial Mucosal Integrity The bronchial mucosa serves as the first line of defense against inhaled pathogens, particles, and irritants.
oral
Administered via oral.
Quality Indicators
What to look for
- Naturally occurring compound
- Multiple peer-reviewed studies available
Frequently Asked Questions
References (4)
- [1][Monaselidze JR et al. (2011). Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bull Exp Biol Med (2011)
- [2][Khavinson VK et al. (2012). Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med (2012)
- [3][Kuzubova NA et al. (2015). Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. Bull Exp Biol Med (2015)
- [4][Khavinson VK et al. (2021). Peptide Regulation of Gene Expression: A Systematic Review. Molecules (2021)
TAT-Beclin-1 Conjugate Peptide
TAT-Beclin-1 is an engineered cell-penetrating autophagy-inducing peptide combining the HIV TAT transduction domain with a Beclin-1-derived sequence. It potently induces autophagy across cell types and demonstrates broad-spectrum antiviral activity against HIV, Sindbis, chikungunya, and West Nile viruses.
TB-4 Fragment (Ac-SDKP)
Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) is a naturally occurring tetrapeptide released from thymosin beta-4 by prolyl oligopeptidase. It is a potent anti-fibrotic agent with significant research in cardiac and renal fibrosis, hematopoietic stem cell regulation, and inflammation.